NCT02249988View on ClinicalTrials.gov

Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Chronic Hepatitis B
Interventions
DRUG

ABX203 therapeutic Hepatitis B vaccine treatment arm

Trial Locations (12)

1023

Auckland City Hospital, Auckland

2050

Royal Prince Alfred Hospital, Camperdown

2145

Westmead Hospital, Westmead

2170

Liverpool Hospital, Liverpool

3004

The Alfred Hospital, Melbourne

3050

Royal Melbourne Hospital, Parkville

3065

St Vincent's Hospital Melbourne, Fitzroy

3084

Austin Hospital, Heidelberg

3168

Monash Medical Centre Clayton, Clayton

3240

Waikato Hospital, Hamilton West

6000

Royal Perth Hospital, Perth

6021

Wellington Hospital, Wellington

Sponsors

Lead Sponsor

Abivax S.A.
All Listed Sponsors
lead

Abivax S.A.

INDUSTRY

NCT02249988 - Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B | Biotech Hunter | Biotech Hunter